In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Pfizer's combination of Talzenna and Xtandi has shown a notable improvement in overall survival rates for patients with metastatic castration-resistant prostate cancer (mCRPC) in a late-stage study.

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...